More than  of drug trials for Alzheimers disease during the past decade have failed according to a study There is an urgent need to increase the number of potential therapies being investigated say US scientists Only one new medicine has been approved since  they report in the journal   The drug failure rate is troubling and higher than for other diseases such as cancer says   Dr Jeffrey Cummings of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas and colleagues examined a public website that records clinical trials Between  and  they found  of trials of drugs aimed at preventing curing or improving the symptoms of Alzheimers had failed or been discontinued  This compares with a failure rate of  for cancer drugs The failure rate was especially troubling given the rising numbers of people with dementia said Dr Simon Ridley of Alzheimers Research UK The authors of the study highlight a worrying decline in the number of clinical trials for Alzheimers treatments in more recent years he said  There is a danger that the high failure rates of trials in the past will discourage pharmaceutical companies from investing in dementia research  The only way we will successfully defeat dementia is to continue with high quality innovative research improve links with industry and increase investment in clinical trials Dr Eric Hill of the School of Life and Health Sciences at Aston University said more research was needed to understand the complex mechanisms behind the disease   The development of better experimental models that could be incorporated into a battery of tests will not only help us to understand the changes that occur in the brains of Alzheimers disease patients but also provide tools for the development of new drug treatments that could slow or stop the onset of disease he told BBC News Alzheimers disease is the most common form of dementia It affects more than  people in the UK and costs the economy bn a year 